Stories about Alife Health

Subscribe to our exclusive mailing list and get the freshest stories from Alife Health.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

This startup wants to bring clarity to the complex world of IVF

Published May 5, 2021
About 180 million people globally suffer from infertility. In the United States, one in eight families have trouble conceiving. The statistics are only getting worse, as male infertility and miscarriages continue to increase.

Alife Health, a San Francisco-based startup founded by Paxton Maeder-York, thinks it can help. The startup wants to use artificial intelligence to increase fertility outcomes. Specifically, it wants to optimize in vitro fertilization, a fertility treatment that requires a series of expensive and emotionally taxing procedures with varied success rates.

Founded last year, the startup just raised a $9.5 million seed round, led by Lux Capital. Other investment firms include Amplo, IA Ventures and Springbank Collective, as well as angel investors such as Anne Wojcicki, the founder and CEO of 23andMe; Fred Moll, the founder of Intuitive Surgical and Auris; and Amira Yahyaoui, the founder of Mos and Sequoia Scout.


“I personally believe that improving the quality of care through personalized treatments and reducing costs by increasing the success outcome rate can be incredibly impactful here, not just for the broader population but also specifically for minority groups,” Maeder-York said.

The founder began his career building surgical robots to fight lung cancer at Auris Health, which was acquired by Johnson & Johnson in 2019. Now, he’s onto finding a way to help physicians and patients go through the process of IVF.
Read moreRead less

WSJ: Lux Capital Leads Seed Financing for Fertility-Tech Startup Alife

Published May 3, 2021
Lux Capital has led a $9.5 million seed financing for Alife Health Inc., a startup planning to use artificial intelligence to give patients their best shot at success when undergoing in vitro fertilization.

In vitro fertilization is the most common type of assisted reproductive technology, according to the Centers for Disease Control and Prevention. It involves fertilizing an egg with sperm in the lab and later transferring an embryo or embryos to the woman. The success of IVF depends on several factors, including the woman's age and the quality of the eggs and semen.

San Francisco-based Alife formed last year and has established a consortium of in vitro fertilization clinics, physicians and researchers that gives it access to de-identified patient data, according to founder and Chief Executive Paxton Maeder-York. Alife uses artificial intelligence to identify patterns in the data that could help clinicians make personalized recommendations for people going through the IVF process, he said.

Alife expects, for example, that AI could help improve decisions around the transfer of embryos and other steps in the in vitro fertilization process. It plans to demonstrate the value of its approach through clinical research, Mr.
Maeder-York said, adding, "It's incumbent on us to show there is a clinical benefit."

Lux Partner Deena Shakir, who has joined the Alife board, said she sees potential for Alife to improve IVF outcomes and make IVF a more accessible and inclusive process to patients.

Infertility is common. About 9% of men and about 11% of women of reproductive age in the U.S. have experienced fertility problems, according to the federal Eunice Kennedy Shriver National Institute of Child Health and Human Development.

Alife intends to provide its software to in vitro fertilization clinics, which could offer Alife services as part of their standard service or as an added benefit, Mr. Maeder-York said. He declined to discuss when Alife's products will become available or what they will cost, but said he sees potential for self-insured employers to pay for Alife services for their employees and for
commercial insurers to cover Alife services.

Before founding Alife, Mr. Maeder-York was a product manager for Auris Health Inc., a medical-robotics company backed by Lux Capital and other investors, that was acquired by Johnson & Johnson for $3.4 billion in 2019.

In addition to Lux, the seed financing included investment from Amplo, IA Ventures, Springbank Collective, New York Presbyterian Ventures, as well as several individuals.
Read moreRead less

Women struggling to get pregnant face huge bills for infertility treatments. Alife Health is using AI to make IVF more affordable.

Published May 3, 2021
Data shows that one in eight women struggle with infertility. And in vitro fertilization, the most popular treatment they seek to help them conceive, can cost $20,000 per cycle and often takes several attempts. Since IVF is rarely covered by insurance, the exorbitant price tag is a serious financial barrier for women trying to get pregnant.

"It's clearly an inefficient process at some level," Alife Health founder Paxton Maeder-York told Insider. "And there's opportunity to improve it."

Maeder-York believes artificial intelligence is the future of fertility. His company, Alife Health, is using the technology to innovate the IVF process, with the end goal of making IVF cheaper and more accessible.

The company was just founded last year, but investors have already lined up to back it. Today, Alife Health announced a $9.5 million seed round led by Lux Capital, with other investors like Amplo, IA Ventures, and founder of 23andMe Anne Wojcicki contributing to the fundraise.

Deena Shakir, a partner at Lux Capital who will be joining the company's board, told Insider it was about time for a company like Alife Health.

"There has not been a lot of innovation since the advent of IVF," she said. "There is a massive opportunity for machine learning to transform the IVF experience and ultimately help contribute to advancing human health and health equity."

Alife Health works by collecting a massive data set from fertility clinics across the country and using thousands of prior IVF cycles to decide which embryos will have the highest chance of success. By increasing the effectiveness of each cycle, people could potentially pay for less cycles, making the process significantly more affordable.

The technology is still being developed, but Maeder-York hinted to "keep an eye out for the Alife system sometime next year." He said this new capital is "critical" to taking the company to the "next stage" of being used by doctors in their IVF treatments.

In 2020, investors poured nearly $78 million into fertility tech startups, according to PitchBook data.

Maeder-York said the money will go towards expanding their team, building partnerships with more fertility clinics, and collecting more data.

And, as they collect more data, Maeder-York is careful to avoid biases in their algorithm that have plagued other AI companies.

"We spent a lot of time making sure that we have a lot of diversity in our data, that we have representation from all different types of ethnicities, age groups, diagnoses," he said.

This seed round is only the beginning for Alife Health, which Maeder-York hopes will one day provide personalized treatment plans for IVF patients from start to finish.

"Our team has deep conviction in the value of this type of technology and its ability to help patients," he said.
Read moreRead less

Alife Health Aims To Improve IVF Outcomes With $9.5M Seed

Published May 3, 2021
Investors infused $9.5 million of seed funding into fertility technology company Alife Health, which is building a modern operating system for in vitro fertilization (IVF) designed to improve reproductive outcomes.

Lux Capital led the seed round and was joined by Amplo, IA Ventures and Springbank Collective as well as a group of angel investors that include Anne Wojcicki, Fred Moll and Amira Yahyaoui.

One in eight families struggle with infertility, according to figures from the Centers for Disease Control and Prevention. San Francisco-based Alife Health was founded in 2020 and is leveraging artificial intelligence and data to create personalized treatment insights so clinicians can make better decisions that maximize a patient’s chances of success while also lowering costs and barriers to IVF access.

“Many of us are touched by infertility,” Paxton Maeder-York, founder and CEO of Alife Health, told Crunchbase News. “Typically, IVF is expensive and time-consuming. It can cost an average of $10,000 to $12,000 per cycle and can take an average of three times. We aim to improve success rates across every cycle and bring costs down.”

Before Alife Health, Maeder-York was building surgical robots to fight lung cancer and decided to go back to school to study how AI and machine learning was impacting medicine. One of his focus areas was IVF and the impact on women and the LGBTQ+ community.

One of the biggest challenges to infertility is loss of control by the patient, Maeder-York said. While other companies are focusing on one process along the IVF journey, Alife is working to optimize every step using AI and personalized medicine.

“Starting a family is a personal experience, and if you can’t, it feels like you’ve also lost the ability to control the situation,” he added. “We are re-empowering the patient to make the best choices. If they have the right data, they may be able to make different decisions, such as banking more embryos. Here, the patient is an enormous stakeholder.”

He intends to deploy the new funds in pushing the company to its next stage. He believes Alife Health is already understanding what technology should be built and has received endorsements from doctors and partnerships. The company has 11 full-time employees, and Maeder-York plans to double that by the end of the year in order to scale up to a full ecosystem of platforms that will integrate

The next phase is getting the technology through regulatory submissions and out to patients. There are 500 fertility clinics across the United States, both private and academic institutions, and Alife has been working with some of the largest clinics to build a use case and unbiased dataset over the past year, Maeder-York said.

As part of the investment, Lux Partner Deena Shakir is joining the Alife board. Her focus is on women’s health, which she said is particularly salient. In addition, Alife is bringing equity and diversity into the fertility space that traditionally skewed to middle- and upper-class white families, she said in an interview.

“We’ve been looking at this space for a long time,” she said. “Their focus on health equity and diversity are a major issue with health care at-large, and we’ve seen that come out during COVID. Alife is building in the core of research and working with top academics who are specifically keeping that in check.”
Read moreRead less

Using artificial intelligence to inform IVF

Published Oct 28, 2020
In vitro fertilisation (IVF) is one of several techniques that can help the one in seven couples who will struggle to conceive. An egg is removed from the ovary of the person who will be carrying the child, and artificially fertilised with sperm in a laboratory. The embryo is then returned to the uterus. It can be carried out using eggs and sperm from donors, as well as a pregnant person and their partner, making it a viable option for individuals and couples experiencing infertility for a variety of different reasons.
However, the success rates for IVF are contingent on both the cause of infertility and the age of the person undergoing the procedure. According to the UK NHS, success rates for IVF are around 29% for women under 35, gradually decreasing to only 2% for women aged over 44.

Alife founder and CEO Paxton Maeder-York says: “Successful pregnancies from IVF, which is extremely costly and can have low success rates, rely on a complex set of clinical decisions made by physicians to deliver the optimal care for each patient.”

What is Alife?
Founded in 2020, Alife is a San Francisco-based artificial intelligence (AI) company that has yet to release any products but aims to create a software platform to support clinical decision-making during the IVF process. The company recently raised $9.5m in a seed funding round, which it will use to develop the platform and prepare it for regulatory review.
“The amazing thing about machine learning is that it can incorporate lessons from hundreds of thousands of cases from all over the world to enhance its ability to create customised treatment recommendations,” says Maeder-York. “This can be a huge asset to physicians and patients. Alife’s technology doesn’t replace clinical judgement made by the amazing doctors working in this field; it’s meant to be another tool for them to use to improve efficacy.”
The platform will use clinical data from numerous sources to inform the recommendations it makes to clinicians.
Maeder-York says: “Today, the IVF process is very manual and differs greatly from clinic to clinic. This diversity is actually an asset to the field because what one clinic in one part of the country does may be better for some patients, and the protocols at a different clinic in another part of the country might be best for another group of patients.
“The problem is how to disperse these learnings and deliver them as a tool back to clinicians, and this is exactly what AI can do. It can look at hundreds of thousands of patient experiences and find patterns so that when a new patient comes in for care, we can leverage the learnings from all those previous cases and clinical practices to optimise their chances of success.”
Read moreRead less

Alife Health Builds Artificial Intelligence Tools To Improve In Vitro Fertilization (IVF)

Published Oct 28, 2020
Below is our recent interview with Paxton Maeder-York, the Founder and CEO at Alife Health

Q: Could you provide our readers with a brief introduction to Alife?

A: Alife Health is a company building artificial intelligence tools to improve in vitro fertilization (IVF). 180 million people globally are struggling with infertility, which is growing at an alarming rate. Successful pregnancies from IVF, which is extremely costly and can have low success rates, rely on a complex set of clinical decisions made by physicians to deliver the optimal care for each patient. Alife Health builds software with artificial intelligence to enhance clinical decision making for personalized treatment recommendations, helping doctors maximize a patient’s chances of success while lowering costs.

Q: What’s your mission?

A: Alife Health’s mission is to help people have healthy children.

Q: How can you help physicians to increase a patient’s chances of pregnancy success?

A: Alife Health is creating software both for the clinicians, as well as for the patients, to deliver personalized care at every step of the IVF process. The amazing thing about machine learning is that it can incorporate lessons from hundreds of thousands of cases from all over the world to enhance its ability to create customized treatment recommendations. This can be a huge asset to physicians and patients. Alife’s technology doesn’t replace clinical judgement made by the amazing doctors working in this field, it’s meant to be another tool for them to use to improve efficacy.

Today, the IVF process is very manual and differs greatly from clinic to clinic. This diversity is actually an asset to the field because what one clinic in one part of the country does may be better for some patients, and the protocols at a different clinic in another part of the country might be best for another group of patients. The problem is how to disperse these learnings and deliver them as a tool back to clinicians, and this is exactly what AI can do. It can look at hundreds of thousands of patient experiences and find patterns so that when a new patient comes in for care, we can leverage the learnings from all those previous cases and clinical practices to optimize their chances of success.

One example of that is the prioritization of transferable embryos. Using pattern recognition, our software can reference our large, diverse data set and make a recommendation to the clinician on which embryos will be the most successful for that particular patient. (We have built a consortium of the largest and leading clinics around the U.S. and internationally to create a substantial and very diverse data set of prior cases, their treatment, and their outcomes.) However, this is just one piece of a broader ecosystem of products to personalize IVF care and promote transparency for the patient across their journey.
Donec condimentum euismod quam scelerisque porttitor vel. Etiam risus turpis dignissim ultricies venenatis nunc, mi, sed nibh. Volutpat, sit adipiscing mauris, in. Odio imperdiet magna hendrerit arcu. Nibh volutpat vitae viverra nunc dignissim. Blandit sed volutpat nascetur non etiam curabitur molestie tempor purus. Aliquet pharetra volutpat, metus varius sollicitudin nisi. Faucibus et laoreet fringilla egestas pharetra suspendisse. Varius sollicitudin posuere senectus imperdiet. Nunc lacinia tincidunt et feugiat euismod laoreet. Ultricies nec ultrices platea ac nec. Neque aliquam felis consequat dolor vitae, sodales. Diam elit neque, quis vitae dolor vitae amet.

Massa dictumst in elementum lectus ut ut vel. Gravida diam at scelerisque justo. In ullamcorper hendrerit duis id. Sit curabitur arcu eget arcu. Egestas tristique sit at massa. Sed pharetra urna et in pretium volutpat enim urna. Aenean sed pellentesque aliquet cras arcu, diam. Quis facilisi id porttitor tincidunt massa amet sapien ornare. Enim enim condimentum neque, imperdiet fermentum, vel. Dolor sit lacus volutpat diam mattis. Parturient in pellentesque malesuada ac fermentum. Nibh suspendisse fringilla ut amet egestas iaculis interdum.

Cursus lorem sagittis gravida augue sed. Cursus urna arcu neque, ut in mollis velit amet mattis. Elementum nunc, netus suspendisse in purus ut. Purus lorem ultrices vitae nunc ullamcorper mauris a, vivamus. Vel non, amet, quisque erat nisi, nisl orci libero. Tempor leo et sit blandit tincidunt. Duis in laoreet blandit nunc, leo a. Enim sem lectus purus magnis cras consectetur blandit. Sollicitudin viverra odio leo massa fames.
Neque id placerat accumsan cursus. Ut etiam suscipit sed euismod egestas netus. Mi, mauris volutpat blandit sapien ullamcorper pulvinar. Laoreet nunc, egestas id porttitor dignissim senectus quis consectetur. Ultrices aliquet pellentesque risus facilisi tellus diam. Feugiat felis urna, duis convallis ullamcorper molestie elementum nibh. Varius lobortis tristique vestibulum egestas nulla sed aliquam tincidunt. Arcu ipsum diam mauris ultrices lorem. Quam sem etiam viverra malesuada donec. Fames diam arcu suscipit in dictum sit in adipiscing. Eleifend nec felis adipiscing morbi augue lorem pellentesque elementum morbi.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut arcu adipiscing ut ligula ultricies commodo tempus mattis quam. Purus vitae posuere vulputate feugiat egestas nunc viverra. Donec venenatis diam facilisis quam augue. Eget sed elementum, nec diam enim. Tortor malesuada vel laoreet egestas sit ornare a fermentum. Tempus leo, orci, imperdiet urna et bibendum at. Sit urna, tempus, tortor malesuada mauris ipsum. In sit at nibh pretium faucibus at. Eget ac tempor nunc integer tempor dolor id lectus. Porta tellus imperdiet venenatis, eget elementum, ridiculus sit magna vitae. Ullamcorper enim varius blandit arcu, tincidunt aliquet feugiat. Posuere lacus, amet fusce dictum quam. In velit ut ac mattis tempus morbi.
Amet praesent eget nisl, at. Facilisi in quis at erat malesuada dolor. Tempor commodo etiam libero semper ullamcorper dui in mattis penatibus. Purus feugiat vestibulum, ac, risus eu consequat turpis est. Nulla est integer potenti curabitur facilisis nibh sit. Enim in est malesuada velit, sit.

Sagittis hendrerit mattis aliquet et semper. Interdum volutpat, porta purus eu. Semper dictum viverra amet laoreet bibendum nibh viverra. Justo consectetur sem neque ullamcorper eleifend facilisis cras. Nulla placerat pellentesque vulputate id felis, odio nisl eget fermentum. Adipiscing neque nisl tortor et.
Sed urna etiam nulla quis elit. Nisl nunc, ut vitae egestas pellentesque. Porttitor pellentesque ut sed nisl. In leo mauris ipsum urna. Eleifend aliquam tincidunt vitae faucibus tempus ipsum. Lacinia massa vitae molestie risus. Adipiscing etiam massa penatibus purus ac pharetra. Ornare sed ultrices sodales commodo. Suspendisse nulla rutrum pulvinar a. Vulputate aliquet quisque sed pharetra interdum. Convallis cursus risus in eget dolor aliquet parturient duis.
Read moreRead less

Fertility in Crisis: Alife Health Aims to Improve Health Equity and Outcomes Using AI

Published May 3, 2021
Alife Health, a company that addresses infertility through artificial intelligence tools, raises $9.5 million seed led by Lux Capital.

1 in 8 families now struggle with infertility. Studies show that the average healthy couple has a 20 percent natural fertility rate per cycle, and miscarriages in women are increasing by about 1 percent each year. Additionally, Black and Latinx women are less likely to access fertility care and have a successful IVF pregnancy. As fertility continues to be in crisis, new artificial intelligence (AI) supported technology looks to promote health equity and better outcomes. Alife Health, a technology company founded in 2020, is building AI tools designed to improve fertility care, starting with in vitro fertilization (IVF). Alife Health’s technology aims to empower clinical decision making with personalized treatment recommendations to help clinicians maximize a patient’s chances of success while lowering costs and barriers to access.

Today there are significant drawbacks to treating infertility. IVF is prohibitively expensive, often requires multiple cycles, is physically and emotionally onerous, and is still rarely covered by insurance. Successful pregnancies from IVF rely on a complex set of clinical decisions made by physicians to deliver the optimal care for each patient. Using advanced computational methods, Alife Health is building a modern operating system for IVF designed to improve reproductive outcomes at a time when 180 million people globally are struggling with infertility.

Alife Health announced today it has raised $9.5 million in Seed financing led by Lux Capital (with Partner Deena Shakir joining the Board) with participation from Amplo (Sheel Tyle), IA Ventures (Jesse Beyroutey), Springbank Collective as well as a number of angels including Anne Wojcicki (founder and CEO of 23andMe), Fred Moll (Founder of Intuitive Surgical and Auris), Amira Yahyaoui (Founder of Mos and Sequoia Scout), Arthur Patterson (founder of Accel), Dr. Tom Lee (Founder of One Medical Group and Galileo Health) and the founders of Ramp and Headway. Additionally, Alife Health has a number of notable advisors, including Tatyana Beldock (formerly new ventures at J&J) and Dr. Kim Thornton, a board-certified Reproductive Endocrinologist at Boston IVF and a Clinical Professor at Harvard Medical School. Alife Health’s team includes engineers and scientists from Harvard, Stanford, MIT and Johns Hopkins and it has created a consortium of clinical partnerships with leading clinics and cutting edge physicians and researchers to bring clinical value to patients.

"There are many aspects to IVF that can be improved through data-driven personalized medicine," says Paxton Maeder-York, founder and chief executive officer of Alife Health. "From alleviating family planning pressure for working women to supporting family creation in the LGBTQ+ community, improving IVF has the potential to help parents realize their dreams of having a healthy child. I’ve had several family members who’ve relied on IVF and know firsthand the societal impact improving infertility care can have."

Maeder-York started his career building surgical robots to fight lung cancer at Auris Health, which sold to Johnson & Johnson in 2019. He holds a bachelor’s degree in Biomedical Engineering, a master’s degree in Data Science, and an MBA from Harvard University. Maeder-York founded Alife Health in 2020 to empower physicians and patients to make the best clinical decisions possible through advanced analytics delivered in an optimally designed, medical-grade software ecosystem.

"We’ve applied advanced machine learning in countless other medical imaging fields, but we are only just starting to scratch the surface on how it can be used to advance family and reproductive health. There is a tremendous opportunity for technology to transform the IVF experience and ultimately contribute to advancing human health and health equity. Alife Health is leading this effort with its unique, technology-forward, human-centered approach," said Deena Shakir, partner at Lux Capital. "Paxton has assembled an all-star team of scientists, engineers and designers, and an incredibly respected group of scientific advisors and clinical partners to bring the benefit of this technology to patients, with inclusivity and equity at the core of the mission. I have spent a long time looking for the cutting edge technology that can improve fertility options, and I could not be more excited to back this breakthrough team."

"There is increasing evidence that race and ethnicity may impact outcomes in fertility treatment," says Dr. Kim Thornton, a board-certified Reproductive Endocrinologist at Boston IVF and a Clinical Professor at Harvard Medical School, who has been appointed to the American Society for Reproductive Medicine Diversity, Equality and Inclusion Task Force. "It is important to first acknowledge that differences exist and then explore, through the use of artificial intelligence, what those factors may be. What we learn will then allow us to address these specific factors so that we might begin to eliminate those disparities."

ABOUT LUX CAPITAL

Lux Capital is a venture capital firm founded in 2000 that invests in counter-conventional, early-stage emerging science and technology companies. With offices in New York City and Silicon Valley, Lux manages $2.4 billion in assets across multiple funds. For more information please visit www.luxcapital.com or follow us on Twitter @Lux_Capital.

ABOUT ALIFE HEALTH

Alife Health is a fertility technology company building a modern operating system for IVF. Founded with the mission of helping people have healthy children, it leverages cutting edge computational methods with the hopes of improving reproductive outcomes. Enhancing care with artificial intelligence, it is differentiated in its product approach, scientific rigor and access to data. The company has built a consortium of clinical partnerships with the largest clinics and most renowned physicians in the world to bring significant clinical value to patients. Founded by Paxton Maeder-York in 2020, the company is based in San Francisco and backed by top tier venture capital investors including Lux Capital.
Donec condimentum euismod quam scelerisque porttitor vel. Etiam risus turpis dignissim ultricies venenatis nunc, mi, sed nibh. Volutpat, sit adipiscing mauris, in. Odio imperdiet magna hendrerit arcu. Nibh volutpat vitae viverra nunc dignissim. Blandit sed volutpat nascetur non etiam curabitur molestie tempor purus. Aliquet pharetra volutpat, metus varius sollicitudin nisi. Faucibus et laoreet fringilla egestas pharetra suspendisse. Varius sollicitudin posuere senectus imperdiet. Nunc lacinia tincidunt et feugiat euismod laoreet. Ultricies nec ultrices platea ac nec. Neque aliquam felis consequat dolor vitae, sodales. Diam elit neque, quis vitae dolor vitae amet.

Massa dictumst in elementum lectus ut ut vel. Gravida diam at scelerisque justo. In ullamcorper hendrerit duis id. Sit curabitur arcu eget arcu. Egestas tristique sit at massa. Sed pharetra urna et in pretium volutpat enim urna. Aenean sed pellentesque aliquet cras arcu, diam. Quis facilisi id porttitor tincidunt massa amet sapien ornare. Enim enim condimentum neque, imperdiet fermentum, vel. Dolor sit lacus volutpat diam mattis. Parturient in pellentesque malesuada ac fermentum. Nibh suspendisse fringilla ut amet egestas iaculis interdum.

Cursus lorem sagittis gravida augue sed. Cursus urna arcu neque, ut in mollis velit amet mattis. Elementum nunc, netus suspendisse in purus ut. Purus lorem ultrices vitae nunc ullamcorper mauris a, vivamus. Vel non, amet, quisque erat nisi, nisl orci libero. Tempor leo et sit blandit tincidunt. Duis in laoreet blandit nunc, leo a. Enim sem lectus purus magnis cras consectetur blandit. Sollicitudin viverra odio leo massa fames.
Neque id placerat accumsan cursus. Ut etiam suscipit sed euismod egestas netus. Mi, mauris volutpat blandit sapien ullamcorper pulvinar. Laoreet nunc, egestas id porttitor dignissim senectus quis consectetur. Ultrices aliquet pellentesque risus facilisi tellus diam. Feugiat felis urna, duis convallis ullamcorper molestie elementum nibh. Varius lobortis tristique vestibulum egestas nulla sed aliquam tincidunt. Arcu ipsum diam mauris ultrices lorem. Quam sem etiam viverra malesuada donec. Fames diam arcu suscipit in dictum sit in adipiscing. Eleifend nec felis adipiscing morbi augue lorem pellentesque elementum morbi.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut arcu adipiscing ut ligula ultricies commodo tempus mattis quam. Purus vitae posuere vulputate feugiat egestas nunc viverra. Donec venenatis diam facilisis quam augue. Eget sed elementum, nec diam enim. Tortor malesuada vel laoreet egestas sit ornare a fermentum. Tempus leo, orci, imperdiet urna et bibendum at. Sit urna, tempus, tortor malesuada mauris ipsum. In sit at nibh pretium faucibus at. Eget ac tempor nunc integer tempor dolor id lectus. Porta tellus imperdiet venenatis, eget elementum, ridiculus sit magna vitae. Ullamcorper enim varius blandit arcu, tincidunt aliquet feugiat. Posuere lacus, amet fusce dictum quam. In velit ut ac mattis tempus morbi.
Amet praesent eget nisl, at. Facilisi in quis at erat malesuada dolor. Tempor commodo etiam libero semper ullamcorper dui in mattis penatibus. Purus feugiat vestibulum, ac, risus eu consequat turpis est. Nulla est integer potenti curabitur facilisis nibh sit. Enim in est malesuada velit, sit.

Sagittis hendrerit mattis aliquet et semper. Interdum volutpat, porta purus eu. Semper dictum viverra amet laoreet bibendum nibh viverra. Justo consectetur sem neque ullamcorper eleifend facilisis cras. Nulla placerat pellentesque vulputate id felis, odio nisl eget fermentum. Adipiscing neque nisl tortor et.
Sed urna etiam nulla quis elit. Nisl nunc, ut vitae egestas pellentesque. Porttitor pellentesque ut sed nisl. In leo mauris ipsum urna. Eleifend aliquam tincidunt vitae faucibus tempus ipsum. Lacinia massa vitae molestie risus. Adipiscing etiam massa penatibus purus ac pharetra. Ornare sed ultrices sodales commodo. Suspendisse nulla rutrum pulvinar a. Vulputate aliquet quisque sed pharetra interdum. Convallis cursus risus in eget dolor aliquet parturient duis.
Read moreRead less

Alife raises $9.5M seed financing

Published May 3, 2021
Alife Health announced today that it raised $9.5 million in seed financing for its technology designed to improve fertility care.

San Francisco-based Alife’s AI-based technology aims to offer personalized treatment recommendations to help clinicians improve a patient’s chances of success with in vitro fertilization (IVF) with lower costs and fewer accessibility barriers, according to a news release.

Lux Capital led the seed financing and Alife announced that Lux partner Deena Shakir will join its board as well. Amplo, IA Ventures and Springbank Collective also participated in the round, Alife said.

A number of angels contributed to the funding, including Anne Wojcicki, Fred Moll, Amira Yahyaoui, Arthur Patterson, Dr. Tom Lee and the founders of Ramp and Headway, Alife said in the release.

“There are many aspects to IVF that can be improved through data-driven personalized medicine,” Alife Health founder & CEO Paxton Maeder-York said in the release. “From alleviating family planning pressure for working women to supporting family creation in the LGBTQ+ community, improving IVF has the potential to help parents realize their dreams of having a healthy child. I’ve had several family members who’ve relied on IVF and know firsthand the societal impact improving infertility care can have.”
Donec condimentum euismod quam scelerisque porttitor vel. Etiam risus turpis dignissim ultricies venenatis nunc, mi, sed nibh. Volutpat, sit adipiscing mauris, in. Odio imperdiet magna hendrerit arcu. Nibh volutpat vitae viverra nunc dignissim. Blandit sed volutpat nascetur non etiam curabitur molestie tempor purus. Aliquet pharetra volutpat, metus varius sollicitudin nisi. Faucibus et laoreet fringilla egestas pharetra suspendisse. Varius sollicitudin posuere senectus imperdiet. Nunc lacinia tincidunt et feugiat euismod laoreet. Ultricies nec ultrices platea ac nec. Neque aliquam felis consequat dolor vitae, sodales. Diam elit neque, quis vitae dolor vitae amet.

Massa dictumst in elementum lectus ut ut vel. Gravida diam at scelerisque justo. In ullamcorper hendrerit duis id. Sit curabitur arcu eget arcu. Egestas tristique sit at massa. Sed pharetra urna et in pretium volutpat enim urna. Aenean sed pellentesque aliquet cras arcu, diam. Quis facilisi id porttitor tincidunt massa amet sapien ornare. Enim enim condimentum neque, imperdiet fermentum, vel. Dolor sit lacus volutpat diam mattis. Parturient in pellentesque malesuada ac fermentum. Nibh suspendisse fringilla ut amet egestas iaculis interdum.

Cursus lorem sagittis gravida augue sed. Cursus urna arcu neque, ut in mollis velit amet mattis. Elementum nunc, netus suspendisse in purus ut. Purus lorem ultrices vitae nunc ullamcorper mauris a, vivamus. Vel non, amet, quisque erat nisi, nisl orci libero. Tempor leo et sit blandit tincidunt. Duis in laoreet blandit nunc, leo a. Enim sem lectus purus magnis cras consectetur blandit. Sollicitudin viverra odio leo massa fames.
Neque id placerat accumsan cursus. Ut etiam suscipit sed euismod egestas netus. Mi, mauris volutpat blandit sapien ullamcorper pulvinar. Laoreet nunc, egestas id porttitor dignissim senectus quis consectetur. Ultrices aliquet pellentesque risus facilisi tellus diam. Feugiat felis urna, duis convallis ullamcorper molestie elementum nibh. Varius lobortis tristique vestibulum egestas nulla sed aliquam tincidunt. Arcu ipsum diam mauris ultrices lorem. Quam sem etiam viverra malesuada donec. Fames diam arcu suscipit in dictum sit in adipiscing. Eleifend nec felis adipiscing morbi augue lorem pellentesque elementum morbi.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut arcu adipiscing ut ligula ultricies commodo tempus mattis quam. Purus vitae posuere vulputate feugiat egestas nunc viverra. Donec venenatis diam facilisis quam augue. Eget sed elementum, nec diam enim. Tortor malesuada vel laoreet egestas sit ornare a fermentum. Tempus leo, orci, imperdiet urna et bibendum at. Sit urna, tempus, tortor malesuada mauris ipsum. In sit at nibh pretium faucibus at. Eget ac tempor nunc integer tempor dolor id lectus. Porta tellus imperdiet venenatis, eget elementum, ridiculus sit magna vitae. Ullamcorper enim varius blandit arcu, tincidunt aliquet feugiat. Posuere lacus, amet fusce dictum quam. In velit ut ac mattis tempus morbi.
Amet praesent eget nisl, at. Facilisi in quis at erat malesuada dolor. Tempor commodo etiam libero semper ullamcorper dui in mattis penatibus. Purus feugiat vestibulum, ac, risus eu consequat turpis est. Nulla est integer potenti curabitur facilisis nibh sit. Enim in est malesuada velit, sit.

Sagittis hendrerit mattis aliquet et semper. Interdum volutpat, porta purus eu. Semper dictum viverra amet laoreet bibendum nibh viverra. Justo consectetur sem neque ullamcorper eleifend facilisis cras. Nulla placerat pellentesque vulputate id felis, odio nisl eget fermentum. Adipiscing neque nisl tortor et.
Sed urna etiam nulla quis elit. Nisl nunc, ut vitae egestas pellentesque. Porttitor pellentesque ut sed nisl. In leo mauris ipsum urna. Eleifend aliquam tincidunt vitae faucibus tempus ipsum. Lacinia massa vitae molestie risus. Adipiscing etiam massa penatibus purus ac pharetra. Ornare sed ultrices sodales commodo. Suspendisse nulla rutrum pulvinar a. Vulputate aliquet quisque sed pharetra interdum. Convallis cursus risus in eget dolor aliquet parturient duis.
Read moreRead less

Fertility in Crisis: Alife Health Aims to Improve Health Equity and Outcomes Using AI

Published May 3, 2021
Alife Health, a company that addresses infertility through artificial intelligence tools, raises $9.5 million seed led by Lux Capital.

1 in 8 families now struggle with infertility. Studies show that the average healthy couple has a 20 percent natural fertility rate per cycle, and miscarriages in women are increasing by about 1 percent each year. Additionally, Black and Latinx women are less likely to access fertility care and have a successful IVF pregnancy. As fertility continues to be in crisis, new artificial intelligence (AI) supported technology looks to promote health equity and better outcomes. Alife Health, a technology company founded in 2020, is building AI tools designed to improve fertility care, starting with in vitro fertilization (IVF). Alife Health’s technology aims to empower clinical decision making with personalized treatment recommendations to help clinicians maximize a patient’s chances of success while lowering costs and barriers to access.

Today there are significant drawbacks to treating infertility. IVF is prohibitively expensive, often requires multiple cycles, is physically and emotionally onerous, and is still rarely covered by insurance. Successful pregnancies from IVF rely on a complex set of clinical decisions made by physicians to deliver the optimal care for each patient. Using advanced computational methods, Alife Health is building a modern operating system for IVF designed to improve reproductive outcomes at a time when 180 million people globally are struggling with infertility.

Alife Health announced today it has raised $9.5 million in Seed financing led by Lux Capital (with Partner Deena Shakir joining the Board) with participation from Amplo (Sheel Tyle), IA Ventures (Jesse Beyroutey), Springbank Collective as well as a number of angels including Anne Wojcicki (founder and CEO of 23andMe), Fred Moll (Founder of Intuitive Surgical and Auris), Amira Yahyaoui (Founder of Mos and Sequoia Scout), Arthur Patterson (founder of Accel), Dr. Tom Lee (Founder of One Medical Group and Galileo Health) and the founders of Ramp and Headway. Additionally, Alife Health has a number of notable advisors, including Tatyana Beldock (formerly new ventures at J&J) and Dr. Kim Thornton, a board-certified Reproductive Endocrinologist at Boston IVF and a Clinical Professor at Harvard Medical School. Alife Health’s team includes engineers and scientists from Harvard, Stanford, MIT and Johns Hopkins and it has created a consortium of clinical partnerships with leading clinics and cutting edge physicians and researchers to bring clinical value to patients.

“There are many aspects to IVF that can be improved through data-driven personalized medicine,” says Paxton Maeder-York, founder and chief executive officer of Alife Health. “From alleviating family planning pressure for working women to supporting family creation in the LGBTQ+ community, improving IVF has the potential to help parents realize their dreams of having a healthy child. I’ve had several family members who’ve relied on IVF and know firsthand the societal impact improving infertility care can have.”

Maeder-York started his career building surgical robots to fight lung cancer at Auris Health, which sold to Johnson & Johnson in 2019. He holds a bachelor’s degree in Biomedical Engineering, a master’s degree in Data Science, and an MBA from Harvard University. Maeder-York founded Alife Health in 2020 to empower physicians and patients to make the best clinical decisions possible through advanced analytics delivered in an optimally designed, medical-grade software ecosystem.

“We’ve applied advanced machine learning in countless other medical imaging fields, but we are only just starting to scratch the surface on how it can be used to advance family and reproductive health. There is a tremendous opportunity for technology to transform the IVF experience and ultimately contribute to advancing human health and health equity. Alife Health is leading this effort with its unique, technology-forward, human-centered approach,” said Deena Shakir, partner at Lux Capital. “Paxton has assembled an all-star team of scientists, engineers and designers, and an incredibly respected group of scientific advisors and clinical partners to bring the benefit of this technology to patients, with inclusivity and equity at the core of the mission. I have spent a long time looking for the cutting edge technology that can improve fertility options, and I could not be more excited to back this breakthrough team.”

“There is increasing evidence that race and ethnicity may impact outcomes in fertility treatment,” says Dr. Kim Thornton, a board-certified Reproductive Endocrinologist at Boston IVF and a Clinical Professor at Harvard Medical School, who has been appointed to the American Society for Reproductive Medicine Diversity, Equality and Inclusion Task Force. “It is important to first acknowledge that differences exist and then explore, through the use of artificial intelligence, what those factors may be. What we learn will then allow us to address these specific factors so that we might begin to eliminate those disparities.”

ABOUT LUX CAPITAL

Lux Capital is a venture capital firm founded in 2000 that invests in counter-conventional, early-stage emerging science and technology companies. With offices in New York City and Silicon Valley, Lux manages $2.4 billion in assets across multiple funds. For more information please visit www.luxcapital.com or follow us on Twitter @Lux_Capital.

ABOUT ALIFE HEALTH

Alife Health is a fertility technology company building a modern operating system for IVF. Founded with the mission of helping people have healthy children, it leverages cutting edge computational methods with the hopes of improving reproductive outcomes. Enhancing care with artificial intelligence, it is differentiated in its product approach, scientific rigor and access to data. The company has built a consortium of clinical partnerships with the largest clinics and most renowned physicians in the world to bring significant clinical value to patients. Founded by Paxton Maeder-York in 2020, the company is based in San Francisco and backed by top tier venture capital investors including Lux Capital.
www.alifehealth.com
Read moreRead less
HIPAA and ISO 13485 compliant